Orion OYJ (OTCMKTS:ORINY) Issues Earnings Results

Orion OYJ (OTCMKTS:ORINY) announced its quarterly earnings results on Wednesday. The company reported $0.68 EPS for the quarter, Zacks reports. Orion OYJ had a net margin of 30.25% and a return on equity of 54.09%. The firm had revenue of $623.96 million during the quarter.

Orion OYJ Stock Performance

Shares of ORINY stock remained flat at $56.26 on Friday. 300 shares of the company traded hands, compared to its average volume of 2,001. Orion OYJ has a fifty-two week low of $30.89 and a fifty-two week high of $56.26. The company has a market cap of $15.88 billion, a P/E ratio of 20.76 and a beta of 0.07. The business has a fifty day simple moving average of $47.64 and a 200 day simple moving average of $41.53. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.64 and a quick ratio of 1.48.

Analysts Set New Price Targets

Separately, Jefferies Financial Group raised Orion OYJ from a “hold” rating to a “strong-buy” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Orion OYJ presently has an average rating of “Buy”.

About Orion OYJ

Orion Oyj, also known as Orion Corporation, is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary medicines. Its portfolio includes prescription medicines, over-the-counter products, generic pharmaceuticals and active pharmaceutical ingredients.

The company focuses on several therapeutic areas, including central nervous system disorders, oncology, respiratory diseases, pain management and veterinary medicine. Orion is particularly recognized for treatments related to Parkinson’s disease, as well as its Easyhaler line of inhaled medicines for respiratory conditions.

Founded in Finland in 1917, Orion is headquartered in Espoo.